AMEX · NBY
NovaBay Pharmaceuticals, Inc.
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
Loading market information…
NASDAQ · KTTA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pasithea Therapeutics Corp.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pasithea Therapeutics Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$1.61 |
| $0.00 |
| Q4 2024 | Mar 24, 2025 | -$2.41 | $0.00 |
|---|
| Q3 2024 | Nov 13, 2024 | -$2.87 | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
$23.52$0.00 (0.0%)
Cyclerion Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.38% below the high.
$9.00+$0.39 (+4.57%)
Polyrizon Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.53% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
$0.16-$0.00 (-2.42%)
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
$1.89-$0.24 (-11.27%)
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
